AGO2 and central nervous system cancer: The results suggested that miR-542-5p inhibitor transfection with pristimerin treatment enhance expression of AGO2 and decrease expression of PTPN1 significantly, which mean that pristimerin and miR-542-5p silence had the synergistic effect in glioma cells (Figure 6).